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A B S T R A C T
Valproic acid (VPA) is a well-established anticonvulsant drug that has been increasingly used in the
treatment of many forms of generalized epilepsy. Although there are many reports of adverse effects of
VPA, studies focusing on the concentration–response relationships of VPA and its metabolites in patients
with epilepsy are extremely limited. In this study, a rapid and speciﬁc high performance liquid
chromatography-ultraviolet (HPLC-UV) method to simultaneously detect the concentrations of VPA and
its major hepatotoxic metabolite 2-propyl-4-pentenoic acid (4-ene VPA) in human plasma has been
established, using 2,40-dibromoacetophenone and octanoic acid as the derivatization reagent and
internal standard, respectively. This method was used to analyze plasma samples (n = 64) of Chinese
patients with epilepsy. The results revealed that 4-ene VPA concentrations in Chinese patients were
much higher than those in patients in other countries such as United States and Iran. Signiﬁcant
correlations between aspartate aminotransferase (AST), alanine aminotransferase (ALT) and 4-ene VPA
concentration suggest that the simultaneous determination of VPA and 4-ene VPA is an effective tool for
the prediction of clinical hepatotoxicity in epileptic patients. Furthermore, the present study describes a
less costly and complex technique for the clinical monitoring of VPA plasma levels and the risk of
hepatotoxicity which may be of particular interest in developing countries like China.
Crown Copyright  2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Valproic acid (2-propylpentanoic acid, VPA see Fig. 1) is
generally regarded as the ﬁrst choice agent for most idiopathic
and symptomatic generalized epilepsies.1 The therapeutic con-
centration of VPA ranges from 50 to 100 mg/ml.2,3 One of the most
important clinical adverse effects ascribed to VPA therapy is liver
failure.4 Previous studies indicate that the incidence of hepatotox-
icity caused by VPA is about 1 in 40,000 adults, 1 in 5000 children
and 1 in 500 in the high-risk population in the late 1980s.5
The multiple metabolic pathways involved in VPA biotransfor-
mation give rise to more than 50 known metabolites of the parent
drug.6 Several studies suggest that 2-propyl-4-pentenoic acid (4-
ene VPA) is the most important teratogenic and hepatotoxic
metabolite.7–11 The structure of 4-ene VPA is closely related to the
known hepatotoxicants, hypoglycin and 4-pentenoic acid (4-PA).* Corresponding author. Tel.: +86 136 0978 4669; fax: +86 20 3994 3000.
E-mail address: huangmin@mail.sysu.edu.cn (M. Huang).
e These authors contributed equally to this work.
1059-1311/$ – see front matter . Crown Copyright  2011 British Epilepsy Association
doi:10.1016/j.seizure.2011.10.002In a rat model, 4-ene VPA and its b-oxidation metabolite 2-propyl-
2,4-pentadienoic acid (2,4-diene VPA see Fig. 2) can produce severe
hepatic microvesicular steatosis.12 Another study in rats showed
that VPA hepatotoxicity is signiﬁcantly correlated with liver
concentrations of 4-ene VPA and that toxicity can be predicted by
the urinary excretion of total 4-ene VPA.11 All of these ﬁndings
suggest that monitoring the concentration of VPA and 4-ene VPA in
blood may help to reduce the risk of toxicity in humans and that a
reliable quantitative method that allows simultaneous determi-
nation of VPA and 4-ene VPA in plasma is warranted.
Although several methods have been established to detect the
plasma concentrations of VPA and 4-ene VPA separately,13–17 there
are only two published reports describing simultaneous determi-
nation of VPA and 4-ene VPA using high performance liquid
chromatography–tandem mass spectrometry (HPLC–MS/MS) in
human plasma collected from the United States18 and China,19
respectively. Although the method had good reproducibility and
accuracy, it is commonly known that there are some limitations of
HPLC–MS/MS in clinical pharmacokinetic monitoring. These are
related to the ease of hardware and software use, the instrument
performance, the practicability of HPLC–MS/MS assays in a routine. Published by Elsevier Ltd. All rights reserved.
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particularly for some developing countries like China.
With the background mentioned above, the objectives of the
present study were: (1) to develop a cost-effective, rapid and
efﬁcient method for the simultaneous separation and quantiﬁca-
tion of VPA and 4-ene VPA in human plasma by use of liquid–liquid
extraction procedure and high performance liquid chromatogra-
phy-ultraviolet (HPLC-UV) and (2) to evaluate the correlations of
the plasma VPA and 4-ene VPA concentrations with clinical
adverse effects such as hepatotoxicity in Chinese patients with
epilepsy.
2. Subjects and methods
2.1. Patient enrollment and plasma sample collection
This study was carried out between November 2010 and May
2011 in 64 epileptic outpatients at the Department of Neurology at
the First Afﬁliated Hospital of Sun Yat-sen University. All of the
subjects (age 21.8  16.1 years, body weight 51.9  18.9 kg) were
Southern Han Chinese in origin, and the demographic characteristics
of the patients see Table 3. All patients took divalproex sodium at 8–
30 mg/kg/day twice daily as mono-therapy for at least 1 month.
Samples were collected following patients’ informed consent. Human
plasma samples treated with anticoagulant sodium citrate from
healthy plasma donors were obtained from the Central Laboratory of
the Blood Transfusion Service of Guangzhou, Guangdong, China.
Blood samples (2 ml) for drug assays were usually obtained about
12 h after the evening dose. The plasma was separated by
centrifugation and kept at 80 8C until analysis. All clinical
experiments were approved by the Human Investigation Ethics
Committee of School of Pharmaceutical Sciences, Sun Yat-sen
University, Guangzhou, China (Clinicaltrials.gov Identiﬁer No.
NCT01172626).
2.2. Reagents and chemicals
VPA, 4-ene VPA, octanoic acid (internal standard, IS) and 2,40-
dibromoacetophenone was obtained from Tokyo Chemical Indus-
try Co., Ltd. (Tokyo, Japan), TRC Companies, Inc. (Boston, MA, USA),
Sigma–Aldrich, Inc. (St. Louis, MO, USA) and ALFA AESAR Co., Ltd.
(Ward Hill, MA, USA), respectively. The purity of all reagents was
above 98%. Methanol and ethyl acetate (HPLC grade) were obtained
from Tedia Company, Inc. (Fairﬁeld, OH, USA). Divalproex sodium
(Depakote; tablets) was obtained from Sanoﬁ-Aventis Company
(Paris, France). All other reagents were of analytical grade or HPLC
grade when appropriate.
2.3. Preparation of standard solutions and quality control samples
The stock standard solutions were diluted with methanol to
obtain working solutions at concentrations over 0.05–2.0 mg/ml
for VPA and 5–200 mg/ml for 4-ene VPA. A standard stock solution
of octanoic acid (IS) at 10 mg/ml in methanol was diluted to aCOOH COOH
  valproic acid (VPA)   2-propyl-4-pentenoic ac
Fig. 1. Structure of valproic acid (VPA), 2-propyl-4-peworking solution of 1 mg/ml. Stock solutions and working
solutions were stored at 20 8C and 4 8C, respectively. The
calibration standards and quality control (QC) samples were
prepared by spiking blank human plasma with standard working
solutions during validation and incorporated in each assay run.
Calibration standards were made at concentrations of 5, 10, 20, 40,
80, 160 and 200 mg/ml for VPA and 0.5, 1, 2, 4, 8, 16 and 20 mg/ml
for 4-ene VPA, respectively. Quality control samples were prepared
at concentrations of 10, 40 and 160 mg/ml for VPA and 1, 4, and
16 mg/ml for 4-ene VPA, respectively (see Fig. 2).
2.4. Sample extraction and instrumental analyses
For blank samples, standard working solutions (20 ml of VPA,
4-ene VPA and IS, respectively) were added into 140 ml blank
plasma sample in 10 ml centrifuge tube then vortex-mixed. The
human plasma samples were acidiﬁed to pH 4 with hydrochloric
acid (1 M, 200 ml) and extracted with ethyl acetate (1.5 ml, 5 min)
by use of a vortex mixer for 1 min. After centrifugation at 4000  g
for 10 min, the supernatant was transferred to a clean centrifuge
tube and mixed with 10 ml triethylamine and 50 ml 2,40-
dibromoacetophenone solution (12 mg/ml in methanol). The
mixture was held for 40 min in a water bath at 70 8C and then
evaporated to dryness by general nitrogen gas. The residues were
dissolved in 100 ml mobile phase. An aliquot (10 ml) of the
reconstituent was injected into the HPLC for analysis. The
chromatographic system (Waters, Avondale, CA) consisted of a
pump (Waters 515), an automatic injector (Waters 717 plus), a UV
detector (Waters 486), and a Workstation (Millennium32).
Waters XTerra MS C18 column (5 mm, 4.6 mm  150 mm, Waters,
Milford, USA) was used for the separation. The mobile phase
consisted of methanol/water (76:24, v/v). The analytes were
separated by the analytical column at room temperature.
Detection was performed at wavelength of 254 nm with a ﬂow
rate of 1 ml/min.
2.5. Method validation
The selectivity was investigated in six individual human
plasma samples at the lower limit of quantiﬁcation (LLOQ). The
LLOQ was deﬁned as the lowest concentration on the calibration
curve of the analytes measured with acceptable precision and
accuracy (i.e. relative standard deviation (RSD, refers to the
absolute value of the coefﬁcient of variation (CV)) and relative
error < 20%) and with the response at least ﬁve times to the blank
response (noise). Linearity was assessed by preparing and
analyzing VPA and 4-ene VPA standard samples over 5–200 mg/
ml and 0.5–20 mg/ml, respectively, with seven concentration
points in human plasma. For determining the intra-day accuracy
and precision, ﬁve aliquots of QC samples of VPA and 4-ene VPA
were analyzed on the same day. The inter-day accuracy and
precision were assessed by analysis of ﬁve precision and accuracy
batches on 5 different days. The stability of analytes was assessed
by determining QC samples at three concentrations with ﬁveCOOH
id (4-ene VPA) octanoic acid (IS) 
ntenoic acid (4-ene VPA) and octanoic acid (IS).
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conditions including room temperature for 4 h, three freeze–thaw
cycles, and 20 8C for 1 month.
2.6. Biochemical analysis
Biochemical analysis was performed on serum samples using
the Sysmex HST-330 system (Sysmex Corporation, Kobe, Japan).
Analytes included serum concentrations of WBC (white blood cell,
109/L), neutrophils (N), neutrophils percentage (NP), RBC (red
blood cell, 1012/L), PLT (platelet, 109/L), Hb (hemoglobin, g/L),
BUN (blood urea nitrogen, mmol/L), CR (creatinine, mmol/L),A
U
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Fig. 2. Representative chromatograms of VPA, 4-ene VPA and IS in human plasma. (A) Bl
respectively, and IS at 1 mg/ml; (C) human plasma from one patient 12 h after dosing.and BUN/CR (blood urea nitrogen to creatinine ratio), serum
activities (U/L) of ALT (alanine aminotransferase), AST (aspartate
aminotransferase), LDH (lactate dehydrogenase), GGT (gamma
glutamyltransferase), and ALP (alkaline phosphatase).
2.7. Data analyses
Concentrations of VPA and 4-ene VPA were presented as mg/ml.
Data analyses were performed using SPSS 17.0 for Windows.
Groups were compared using nonparametric tests. Mann–Whitney
U-test was used for comparisons between two groups. Data were
expressed as mean  SD.utes
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ank human plasma; (B) human plasma spiked with VPA, 4-ene VPA at 5, 0.5 mg/ml,
Table 1
Intra- and inter-day precision and accuracy data for assays of VPA and 4-ene VPA in human plasma by HPLC-UV (n = 5).
Compound Nominal concentration (mg/ml) Precision Accuracy (mean
relative error, %)
Mean  SD RSDa (%)
Intra-day VPA 10 10.3  0.52 5.02 3.14
40 40.5  2.11 5.11 1.37
160 167  8.36 5.00 4.46
4-ene VPA 1 1.08  0.06 5.68 7.50
4 3.88  0.48 12.4 2.96
16 16.9  1.73 10.2 5.68
10 10.3  0.14 1.43 2.63
Inter-day VPA 40 41.8  1.07 2.56 4.41
160 170  3.27 1.92 6.30
4-ene VPA 1 1.11  0.03 2.72 11.0
4 3.92  0.21 5.39 1.29
16 17.0  0.06 0.30 6.04
a RSD = relative standard deviation.
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3.1. Method validation
For VPA and 4-ene VPA, the calibration curve was linear over the
range of 5–200 mg/ml and 0.5–20 mg/ml, respectively. The LOQ for
both components was 5 and 0.5 mg/ml, respectively; and the intra-
and inter-day precision were lower than 12.4%, the intra- and
inter-day accuracy were within the range of 3.0% to 7.5% (Table
1). No signiﬁcant degradation of VPA and 4-ene VPA in plasma was
observed under various storage conditions, including at room
temperature for 4 h, frozen-thawed three times, and frozen at
20 8C for 1 month (Table 2). All these parameters meet FDA
requirements for biosample analyses.Table 2
Stability of VPA and 4-ene VPA in human plasma under various storage conditions (n =
Storage condition Compound Nom
20 8C/1 month (stock solution) VPA 10
40
160
4-ene VPA 1
4
16
20 8C/1 month VPA 10
40
160
4-ene VPA 1
4
16
20 8C/3 freeze–thaw cycles VPA 10
40
160
4-ene VPA 1
4
16
4 h at room temperature VPA 10
40
160
4-ene VPA 1
4
16
24 h at room temperature (extracted samples) VPA 10
40
160
4-ene VPA 1
4
16
c Relative error = (overall mean assayed concentration-added concentration)/added c3.2. Plasma concentrations of VPA and 4-ene VPA in patients with
epilepsy
Plasma concentrations of VPA and 4-ene VPA in 64 Chinese
patients with epilepsy treated with divalproex sodium twice daily
for one month are shown in Table 3. The concentrations of VPA and
4-ene VPA ranged from 8.05 to 139 mg/ml and from 1.02 to 12.2 mg/
ml, respectively, with 32.8% samples (21 out of 64) falling out of the
recommended therapeutic monitoring range (50–100 mg/ml). The
total average concentrations of both components in the 64 subjects
are 74.4  28.3 mg/ml and 4.06  2.31 mg/ml, respectively. In the
children group (<16 years old), the concentrations of VPA and 4-ene
VPA are 4.24  1.95 mg/ml/kg/day and 0.19  0.11 mg/ml/kg/day,
respectively. In the adults group (16 years old), the corresponding 5).
inal concentration (mg/ml) Precision
Mean  SD Relative errorc (%)
 10.1  0.62 1.36
 39.4  1.30 1.44
 159  1.61 0.38
 1.11  0.12 10.9
 3.97  0.24 0.71
 16.1  0.69 0.63
 10.2  1.06 1.88
 39.1  4.20 2.28
 156  6.63 2.41
 1.14  0.18 14.3
 4.04  0.36 0.94
 16.5  1.42 3.32
 10.7  0.56 6.69
 38.7  1.54 0.34
 157  4.13 1.77
 0.96  0.13 4.16
 3.96  0.25 1.09
 14.4  0.67 9.94
 9.97  0.76 0.30
 40.1  1.23 0.02
 157  4.57 2.18
 1.13  0.18 13.7
 3.98  0.42 0.61
 15.8  0.48 1.10
 10.5  1.10 4.93
 40.9  3.10 2.29
 158  4.40 0.98
 0.97  0.12 3.24
 4.08  0.73 1.94
 16.0  0.98 -0.16
oncentration  100.
Table 3
Plasma concentrations of VPA and 4-ene VPA and blood biochemical indicators in sixty-four Chinese patients with epilepsy treated with divalproex sodium.a
Group Age Genders Total (n = 64)
<16 (n = 28) 16 (n = 36) Male (n = 42) Female (n = 22)
Age 10.2  4.01 30.9  16.2** 22.3  17.4 20.9  13.6 21.8  16.1
Gender 21 M/7 F 21 M/15 F 42 M 22 F 42 M/22 F
BW 37.1  16.2 63.4  11.6** 54.9  19.9 46.2  15.7 51.9  18.9
VPA (oral intake) 668  271 917  338** 837  295 753  394 808  332
CVPA 76.6  30.6 72.6  26.6 75.9  27.5 71.4  30.1 74.4  28.3
CVPA/D/W
b 4.24  1.95 5.35  2.44* 4.91  1.95 4.80  2.89 4.87  2.29
C4-ene VPA 3.67  2.12 4.36  2.43 4.24  2.57 3.71  1.72 4.06  2.31
C4-ene VPA/D/W
b 0.19  0.11 0.32  0.18** 0.27  0.17 0.26  0.17 0.27  0.17
WBC 7.12  2.21 7.26  2.53 7.45  2.35 6.59  2.35 7.19  2.36
N 2.87  1.07 4.02  2.16 3.60  1.86 3.17  1.69 3.47  1.81
NP 0.41  0.11 0.54  0.11** 0.47  0.10 0.48  0.18 0.48  0.13
RBC 4.79  0.52 4.78  0.49 4.93  0.41 4.44  0.52** 4.78  0.50
PLT 229  90.0 206  53.4 215  69.4 221  83.2 217  73.3
Hb 131  14.2 141  14.9* 141  15.2 125  8.61** 136  15.2
BUN 4.27  0.96 4.37  1.41 4.54  1.30 3.86  0.90 4.33  1.22
CR 65.0  58.8 63.6  14.9 70.9  45.0 49.0  9.86 64.2  38.9
BUN/CR 0.11  0.06 0.07  0.02 0.09  0.05 0.08  0.03 0.09  0.05
ALT 15.1  12.6 26.8  24.8** 25.0  23.4 13.8  6.96 21.3  20.4
AST 27.4  5.96 28.4  17.0 29.2  14.8 25.1  6.44 28.0  13.0
LDH 214  41.7 172  32.4** 195  36.8 181  52.4 191  42.2
GGT 18.9  14.4 24.0  11.3** 23.9  14.6 16.2  5.60 21.4  13.1
ALP 205  76.4 67.8  20.7** 147  88.8 105  85.4 137  88.9
a Data are shown as mean  SD. The comparison of plasma concentrations of VPA and 4-ene VPA and blood biochemical indicators was performed by Mann–Whitney U-test.
b D means VPA dose and W means body weight.
* Correlation is signiﬁcant at p < 0.05 level (2-tailed).
** Correlation is signiﬁcant at p < 0.01 level (2-tailed).
Z.-j. Chen et al. / Seizure 21 (2012) 110–117114values are 5.35  2.44 mg/ml/kg/day and 0.32  0.18 mg/ml/kg/day,
respectively. The statistically signiﬁcant difference in the concentra-
tions of VPA and 4-ene VPA is very evident between these two groups
(p < 0.05). In the gender groups, there is no signiﬁcant difference in the
plasma concentrations of VPA and 4-ene VPA.
3.3. Biochemical analysis
We tested the levels of WBC, N, NP, RBC, PLT, Hb, BUN, CR,
BUN/CR, ALT, AST, LDH, GGT, and ALP in the blood in order to
evaluate the toxic effects of VPA and 4-eve VPA. The average
value for each measure see Table 3, there were 9.37%, 9.37%,
31.3%, 10.9%, 7.81%, 10.9%, 3.85%, 23.1%, 21.9%, 7.81%, 6.25%,
7.81%, 6.25% and 48.9% samples beyond the normal values ofTable 4
Bivariate correlations between the VPA doses, concentrations of VPA, 4-ene VPA and b
DVPA CVPA CVPAdw CeVPA CeVPAdw WBC1 N NP RBC 
DVPA 1
CVPA .190 1
CVPAdw .136 .594** 1
CeVPA .142 .473
** .221 1
CeVPAdw .078 .260* .567** .757** 1
WBC .098 .164 .278 .068 .111 1
N .038 .161 .044 .146 .099 .773** 1
NP .070 .136 .248 .277 .004 .202 .732** 1
RBC .059 .259 .278 .022 .034 .102 .238 .303* 1
PLT S.352* S.381** .152 .126 .125 .350* .234 .153 .030 
Hb .238 .075 .233 .169 .292* .028 .121 .189 .535*
BUN .066 .058 .194 .132 .009 .131 .050 .235 .089 
CR .069 .392* .040 .217 .038 .081 .118 .200 .223 
BUN/CR S.484* .088 .269 .166 .128 .186 .205 S.521** .277 
ALT .401** .054 .068 .282* .176 .143 .111 .010 .226 
AST .304* .187 .061 .359* .102 .094 .266 S.330* .062 
LDH S.308* .094 .102 .053 .223 .237 .079 S.372* .096 
GGT .193 .005 .257 .053 .140 .079 .070 .203 .311*
ALP S.313* .035 .190 .115 .268 .042 .238 S.406** .045 
DVPA = VPA dose; CVPA = concentrations of VPA; CVPAdw= CVPA/dose/body weight; CeVPA
weight. Bold means statistically signiﬁcant correlation.
* Correlation is signiﬁcant at p < 0.05 level (2-tailed).
** Correlation is signiﬁcant at p < 0.01 level (2-tailed).WBC, N, NP, RBC, PLT, Hb, BUN, CR, BUN/CR, ALT, AST, LDH, GGT,
and ALP, respectively.
3.4. Correlations of plasma concentrations of VPA and 4-ene VPA with
biochemical measures
The bivariate correlations of the VPA doses, concentrations of
VPA, 4-ene VPA with blood biochemical indicators in Chinese
patients with epilepsy are shown in Table 4. The concentrations of
VPA and 4-ene VPA had no signiﬁcant correlations with the VPA
dosage. The plasma concentrations of 4-ene VPA were positively
correlated with VPA concentrations (with correlation coefﬁcient (r)
of 0.473, p < 0.01). There was signiﬁcant negative correlation of
PLT (r = 0.352) and BUN/CR (r = 0.484) with VPA dosage, andlood biochemical indicators in Chinese epileptic patients.
PLT Hb BUN CR BUN/CR ALT AST LDH GGT ALP
1
* .186 1
.280 .073 1
S.621** .410* .442* 1
.197 .358 .495* .535** 1
.004 .444** .151 .095 .360 1
.029 .163 .150 .080 .127 .853** 1
.176 .220 .015 .295 .430* .026 .290 1
.031 .532** .047 .121 .364 .570** .302* .191 1
.134 S.331* .115 .184 .274 .224 .013 .606** .285 1
= concentrations of 4-ene VPA; CeVPAdw= concentrations of 4-ene VPA/dose/body
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(r = 0.392) with VPA plasma concentrations (p < 0.05). Further-
more, signiﬁcant positive correlations of the AST (r = 0.359) and
ALT (r = 0.282) with plasma concentrations of 4-ene VPA were
observed in the Chinese patients with epilepsy (p < 0.05).
4. Discussion
4.1. Correlations of concentrations of VPA and 4-ene VPA with adverse
effects of VPA
The anticonvulsant properties of VPA were ﬁrst described in
1967. It has proven to be a broad-spectrum antiepileptic drug
indicated in various forms of epilepsy of adults and the children.
The foremost and most severe concern for anyone taking VPA is its
potential for sudden and severe, possibly fatal, fulminating
impairments in liver and hematopoietic function, especially in
those just starting the medication. In addition, cases in which
individuals taking long-term VPA suffered from renal impairment
have been reported. In this study, we explored the correlation of
the concentrations of VPA and 4-ene VPA with hematopoietic,
renal and hepatic function, which were represented by the levels of
WBC/RBC/PLT, BUN/CR, and ALT/AST/ALP/LDH.
In our study, we found the VPA dosage and/or VPA concentra-
tions was signiﬁcantly negatively correlated with the level of PLT,
which can be interpreted as an indicator of hematopoietic
functions, suggesting that VPA can damage the platelet membrane
by decreasing the production of platelet malonyldialdehyde.20 The
result was consistent with the results of previous studies that
lower platelet levels were noted in patients with higher VPA
concentrations.21,22 The values of BUN/CR, a biochemical marker of
renal dysfunction, were below the normal value in 23.1% patients.
Furthermore, its values signiﬁcantly (p < 0.05) correlated with the
plasma concentrations of VPA. The results suggested that the
clinical monitoring of VPA concentrations may help to minimise its
renal and hematopoietic adverse effects. The serum levels of AST,
ALT, LDH, GGT, and ALP were chosen as markers of hepatocellular
injury.23,24 The results revealed that these biochemical indicators
exceeded normal values in many patients.
To date, several preclinical study have indicated that 4-ene VPA
is the most hepatotoxic metabolite of VPA, but there was very
limited published data about the association between plasmaH3C (CH2)2
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Scheme 1. Reactions of VPA/4-ene VPAlevels of 4-ene VPA and hepatotoxicity,25 except a study conducted
in rats.26 In the present study, signiﬁcant positive correlations of
the AST and ALT with plasma concentrations of 4-ene VPA were
observed in the Chinese patients with epilepsy (p < 0.05). Since
AST and ALT have been most extensively used as routine enzymatic
markers of hepatocellular injury in clinical practice,27 the results
indicated that blood 4-ene VPA concentrations may predict the
hepatotoxicity of VPA.
Further research is ongoing to explore the relationship between
the plasma VPA and 4-ene VPA concentrations, genotypes of the
enzymes and transporters involved in the metabolism and
elimination, efﬁcacy and the adverse reactions of VPA in epileptic
patients treated with divalproex sodium.
4.2. Factors inﬂuencing the concentrations of VPA and 4-ene VPA
VPA exhibits a complex pharmacokinetic proﬁle. Many
investigations have demonstrated that age, dosage and co-
medications are the most important factors that lead to signiﬁcant
intra- and inter- individual pharmacokinetic proﬁles. In our study,
the statistically signiﬁcant difference in the steady state trough
concentrations of VPA and 4-ene VPA was observed between
adults and children groups (p < 0.05). Meanwhile, the study
showed a poor dose–concentration relationship, partially due to
the variability of dosage. This result is consistent with other
reports.28 Some studies have shown that co-medications will
increase the concentration of VPA and aggravate liver damage,
especially the combination of VPA with phenobarbital and
carbamazepine. Now we know that these agents are inducers of
CYP2C9, which will accelerate VPA conversion to 4-ene VPA.
Most importantly, our research found that the concentrations of
VPA and 4-ene VPA vary greatly in different ethnic groups. The
average VPA plasma concentration in Chinese (74.4  28.3 mg/ml)
was comparable to those in the United States (80 mg/ml),18 but less
than those in Iran (294  82.7 mg/ml).29 However, the concentration
of 4-ene VPA (4.06  2.31 mg/ml) in Chinese patients with epilepsy
was much higher than those in the residents in the United States (a
steady state at 250 ng/ml)18 and Iran (129  52.4 ng/ml),29 although
it was comparable with that in a recent study performed in Shanghai,
China (about 4000 ng/ml).19 Previous studies revealed that 4-ene VPA
is predominantly produced by human CYP2C9 with several allelic
variants,30–32 whose inter-population variation in CYP2C9 expressionr
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Z.-j. Chen et al. / Seizure 21 (2012) 110–117116is signiﬁcant.32 For example, Caucasians appear to carry the CYP2C9*2
(8–20%) and CYP2C9*3 (6–10%) variants more frequently than Asians
(0% and 2–5%, respectively).33 Therefore, Asians may have the higher
CYP2C9 activity and higher production of 4-ene VPA compared with
white people.
4.3. Applicability of the present HPLC-UV method in Chinese patients
with epilepsy
In the present study, a simple and efﬁcient HPLC-UV method
for in vivo quantiﬁcation of VPA and its toxic metabolite 4-ene
VPA was developed and validated. As shown in Scheme 1, the
derivatization regent (2,40-dibromoacetophenone) provided a
good chromophore with VPA, 4-ene VPA and IS according to a
previous study.34,35 The chromatograph was equipped with a UV
detector tuned to 254 nm. For VPA and 4-ene VPA, the linearity
range was 5–200 mg/ml and 0.5–20 mg/ml, respectively. The
LLOQ for the two compounds is 5 mg/ml and 0.5 mg/ml,
respectively. This means that the method is sensitive enough
for the concentration determination of VPA and 4-ene VPA in
Chinese patients with epilepsy in whom the concentrations of
VPA and 4-ene VPA approximately ranged between 8.05–139 mg/
ml and 1.02–12.2 mg/ml, respectively. Although some of the
reported HPLC-MS/MS methods are more sensitive than our
HPLC-UV method in determination of the plasma concentrations
of VPA and 4-ene VPA, not all the hospitals in China can afford this
kind of instrument since it is too expensive with the price of RMB
500,000 (about USD 78,000 or EURO 59,000) or more. In fact, few
hospitals in Guangzhou own HPLC-MS/MS instrument. In
contrast, HPLC-UV is very popular in Chinese hospitals because
the set up costs are much lower at RMB 30,000 (about USD 4700
or EURO 3500). The present determination method makes it
possible for most hospitals in developing countries like China to
perform TDM of VPA and to conduct multicenter clinical trials to
obtain more information about the concentration-effect rela-
tionship to guide the clinical use of VPA and guarantee its safety
and efﬁcacy.
5. Conclusion
Our study ﬁrst reports a signiﬁcant relationship between AST/
ALT levels and 4-ene VPA plasma concentration. It suggests that
there are ethnic differences in the plasma concentration of 4-ene
VPA, which mean that monitoring of 4-ene VPA is particularly
important in Chinese populations. The simple, sensitive and cost-
effective HPLC-UV method we have developed here will make
multicenter clinical trials of VPA in China possible, which will
demonstrate whether prospective monitoring of VPA and 4-ene
VPA levels can reduce clinically signiﬁcant hepatotoxicity.
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